Palvella Therapeutics (PVLA) Net Margin (2014 - 2024)
Palvella Therapeutics (PVLA) reported Net Margin of 5150.94% for Q1 2024, down 436820.0% year-over-year from N/an in Q2 2023, and down 7023.38% quarter-over-quarter from 72.31% in Q3 2023.
Palvella Therapeutics (PVLA) Net Margin (2014 - 2024) Analysis & Trends
Palvella Therapeutics (PVLA) has 11 years of Net Margin data on file, last reported at 5150.94% in Q1 2024.
- Net Margin for Q1 2024 came in at 5150.94%, down 436820.0% year-over-year; the trailing twelve-month figure through Sep 2024 was 4.35% (up 5874.0% YoY), and the FY2021 annual result was 163.7%, down 3674.0% from the prior year.
- Net Margin declined to 5150.94% in Q1 2024 per PVLA's latest filing, from 72.31% in the prior quarter.
- Over five years, Net Margin peaked at 12.73% in Q2 2023 and troughed at 5150.94% in Q1 2024.
- A 5-year average of 920.48% and a median of 351.73% in 2022 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2024: Net Margin soared 455056 bps in 2023, then slumped 436820 bps in 2024.
- A 5-year view of Net Margin shows it stood at 660.79% in 2020, then soared by 66 bps to 221.65% in 2021, then sank by 1986 bps to 4622.87% in 2022, then soared by 98 bps to 72.31% in 2023, then sank by 7023 bps to 5150.94% in 2024.
- Business Quant data shows PVLA's Net Margin at 5150.94% in Q1 2024, 72.31% in Q3 2023, and 12.73% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Palvella Therapeutics | 1.49 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -5,150.94% |
| Sep 30, 2023 | -72.31% |
| Jun 30, 2023 | 12.73% |
| Mar 31, 2023 | -782.75% |
| Sep 30, 2022 | -4,622.87% |
| Jun 30, 2022 | -351.73% |
| Mar 31, 2022 | -67.89% |
| Dec 31, 2021 | -221.65% |
| Sep 30, 2021 | -683.00% |
| Jun 30, 2021 | -659.76% |
| Mar 31, 2021 | -38.89% |
| Dec 31, 2020 | -660.79% |
| Sep 30, 2020 | -440.42% |
| Jun 30, 2020 | -40.25% |
| Mar 31, 2020 | -26.67% |
| Dec 31, 2019 | -25.23% |
| Sep 30, 2019 | -17.13% |
| Jun 30, 2019 | -220.52% |
| Mar 31, 2019 | -121.10% |
| Dec 31, 2018 | -1,947.00% |